• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Healthcare·688566.SS
Share

Jiangsu Jibeier Pharmaceutical Co., Ltd. Stocks

CN¥ 26.84Last Updated 13.10.2026

Issuer Rating

5/7
Performance

Favourable

Risk

Limited

Recommendation

Hold

Market Cap

CN¥ 825.19M

CN¥ 26.84
Key Takeaways

Risk factor

Fair trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Strong margins and returns

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Jiangsu Jibeier Pharmaceutical Co., Ltd. is a pharmaceutical enterprise based in Zhenjiang, China, established in 2001. The company's core operations involve the research, development, manufacturing, and sales of a diverse range of pharmaceutical products, including chemical preparations, traditional Chinese medicine formulations, and active pharmaceutical ingredients (APIs). Its product portfolio addresses various health concerns, offering solutions for boosting white blood cell counts, enhancing the immune system, treating joint-related ailments, managing high blood pressure, combating ocular infections, alleviating bronchitis symptoms, and protecting liver function, among others. Additionally, Jiangsu Jibeier is actively engaged in developing new therapeutic drugs, with its pipeline focusing on treatments for conditions such as depression, oncology (tumors), and gastrointestinal disorders.

Company Valuation

Fairly valued
4/7

Considering past and projected metrics, the stock is neither 'expensive' nor 'cheap' compared to its peers. In particular, the stock is reasonably priced on P/E, of fair

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

14.10.2026 03:16

Following in Meta's footsteps, Google has released a new AI model. Will it be able to catch up to its competitors?

14.10.2026 02:46

The headquarters of the world's most valuable oil company was hit by a missile strike

14.10.2026 01:32

Bank of America was fined $1.2 billion for violations related to money laundering

14.10.2026 01:00

Goldman Sachs announced the emergence of two competing AI ecosystems in the U.S. and China

14.10.2026 00:28

Truist is among the top bulls on Meta: it predicts its stock will rise another 35%

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026